[公開日] 2020年3月18日 [最終更新日] 2022年10月17日
国際学会発表一覧
| 発表日 | 発表者名 | 発表学会 | 発表方法 | 発表演題名 | 発表都市 | 発表国 |
|---|---|---|---|---|---|---|
| 2019 Mar 16 | S. Kitano | 2019 Annual Meeting of Taiwan Surgical Association/Tiwan Oncology Society | Oral presentation | Clinical Development of Gene Transferred T Cell Therapy | Taipei | Taiwan |
| 2019 Feb 28 | S. Kitano | 2019 ASCO-SITC Clinical Immunooncology Symposium | Poster presentation | Phase 1 Study of Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Japanese Patients with Advanced Malignancies: Results from the Dose Exploration | San Francisco | United States |
| 2019 Feb 26 | J. Sato | Targeted Anticancer Therapies 2019 | Oral presentation | Dynamic Change in the distribution of cancer types in oncology phase I trials | Paris | France |
| 2018 Dec 5 | K. Yonemori | 41st Annual San Antonio Breast Cancer Symposium | Poster presentation | Long-term follow-up of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial) comparing oral tegafur-uracil (UFT) versus classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant therapy in early breast cancer. | San Antonio | United States |
| 2018 Nov 18 | T. Shimizu | 2018 Molecular Medicine Conference in Philippines | Oral presentation | Harnessing the Power of Precision Medicine – Changing Landscape of Novel Oncology Early Phase 1 Drug Development and Treating Cancers with Implementation of Genome-driven Therapies | Manila | Philippines |
| 2018 Nov 9 | T. Shimizu | The 2nd CUHK Masterclass in Early Phase Clinical Cancer Research Hong Kong | Oral presentation | Practical Issues and Considerations for Conducting Global First-in-Human Phase 1 Trials | Hong Kong | HKSAR, China |
| 2018 Nov 9 | S. Kitano | 2018 Korean Society of Medical Oncology(KSMO) annual meeting | Oral presentation | KSMO-JSMO joint symposium: Immune-monitoring in Japan | Seoul | Korea |
| 2018 Oct 27 | T. Shimizu | The 7th Meeting of Asian National Cancer Centers Alliance (ANCCA) | Oral presentation | Clinical Trials for New Emerging Cancer Drugs - Develop Clinical Trial Unit in Oncology Center- | Jakarta | Indonesia |
| 2018 Oct 22 | Ｎ. Yamamoto | ESMO 2018 | Poster presentation | A Phase 1a/1b study of GDC-0919 (IDO1 inhibitor) as monotherapy and in combination with atezolizumab in Japanese patients (pts) with advanced solid tumors | Munich | Germany |
| 2018 Oct 15 | T. Shimizu | PMDA-ATC Pharmaceuticals Review Seminar 2018 in Myanmar | Oral presentation | Accelerating novel oncology drug development in Japan – Current Status and Future Perspectives – | Nay Pyi Taw | Myanmar |
| 2018 Jun 4 | Ｎ. Yamamoto | ASCO 2018 | Oral presentation | Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567 | Chicago | United States |
| 2018 Jun 1 | T. Shimizu | ASCO 2018 | Oral presentation | First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors | Chicago | United States |
| 2018 Apr 22 | S. Kitano | The 7th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC) | Oral presentation | Anti-PD-1/PD-L1 Antibodies plus Co-Inhibitory Antibodies | Taipei | Taiwan |
| 2018 Apr 21 | T. Shimizu | The 7th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC) | Oral presentation | Anti-PD-1/PD-L1 Antibodies in combination with CSF1R Inhibitors | Taipei | Taiwan |
| 2018 Apr 6 | A. Shimomura | Global Breast Cancer Conference 2018 | Poster presentation | The changing landscape of breast cancer patients in oncology early phase I trials for advanced solid tumors | Incheon | Korea |
| 2018 Mar 5 | T. Koyama | Targeted Anticancer Therapies 2018 | Oral presentation | Impact of Chronic Hepatitis Virus Infection on The Feasibility And Efficacy with Hepatocellular Carcinoma in Phase l Clinical Trials for Asian Patients | Paris | France |
| 2018 Mar 5 | T. Ebata | Targeted Anticancer Therapies 2018 | Poster presentation | Impact of age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular target agents | Paris | France |
| 2018 Mar 5 | A. Shimomura | Targeted Anticancer Therapies 2018 | Poster presentation | Comparison of model-based dose escalation design with rule-based design of phase I oncology trials | Paris | France |
| 2018 Jan 20 | T. Koyama | ASCO Gastrointestinal Cancers Symposium 2018 | Poster presentation | M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with advanced solid tumors | Sun Francisco | United States |
| 2018 Jan 18 | S. Iwasa | ASCO Gastrointestinal Cancers Symposium 2018 | Poster presentation | Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer. | San Francisco | United States |
| 2017 Nov 18 | T. Ebata | ESMO Asia 2017 Congress | Poster presentation | Prognostic factors of survival of patients received immunotherapy in phase 1 trial | Singapore | Singapore |
| 2017 Nov 18 | J. Sato | ESMO Asia 2017 Congress | Poster presentation | Brain metastases-related microRNAs in the advanced breast cancer patients. | Singapore | Singapore |
| 2017 Oct 29 | T. Koyama | AACR-NCI-EORTC International Conference 2017 | Poster presentation | First- in- human phase 1 study of E7090 , a novel selective inhibitors of FGFRs, in patients with advanced solid | Phyradelphia | United States |
| 2017 Sep 10 | A. Shimomura | ESMO 2017 | Poster presentation | Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib | Madrid | Spain |
| 2017 Sep 10 | Ｎ. Yamamoto | ESMO 2017 | Oral presentation | Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors. | Madrid | Spain |
| 2017 Jun 23 | S. Kitano | The 24th Asia Pacific Cancer Conference (APCC) | Oral presentation | Strategy of Combination Immunotherapy | Seoul | Korea |
| 2017 May 17 | J. Sato | ASCO 2017 | Publication Only | Stromal infiltrating CD8+ and CD20+ lymphocytes and CD204+ M2 macrophages but not PD-L1 expression on tumor cells are prognosticators for patients with resectable thymic carcinoma | Chicago | United States |
| 2017 May 17 | K. Sudo | ASCO 2017 | Publication Only | Serum microRNAs to predict the response to nivolumab in patients with esophageal squamous cell carcinoma. | Chicago | United States |
| 2017 Apr 29 | S. Kitano | The 6th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC) | Oral presentation | How to Select the Best Cancer Immunotherapy Combination Trials for Our Patients? | Taipei | Taiwan |
| 2017 Apr 6 | T. Shimizu | The 5th US - Japan Clinical Trials in Oncology Workshop | Oral presentation | Changing of Landscape and New Designs in Early Phase 1 Oncology New Drug Development −Dual Experiences in Japan/US Phase 1 Centers− | Washington, D.C. | United States |
| 2017 Mar 6 | T. Koyama | Targeted Anticancer Therapies 2017 | Poster presentation | Phase 1 clinical trials for bile duct cancer. | Paris | France |
| 2017 Mar 6 | K. Sudo | Targeted Anticancer Therapies 2017 | Poster presentation | Timings of severe toxicity of cytotoxic drugs and molecularly-targeted drugs in phase I trials: a single-institution experience in Japan | Paris | France |
| 2017 Mar 6 | A. Shimomura | Targeted Anticancer Therapies 2017 | Oral presentation | Model-based dose escalation of phase I trials in Japanese patients. – Could it be more efficient than rule-based designs? A single institute experience – | Paris | France |
| 2016 Aug 18 | T. Shimizu | Immuno-Oncology Symposium in TAIWAN | Oral presentation | New Era of Lung Cancer Treatment - How to Adapt I-O Therapy into Clinical Practice – | Kaohsiung | Taiwan |